CELF2

Across TCGA pan-cancer cohorts, CELF2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CELF2 data layer compared with 21 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CELF2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CELF2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where CELF2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.494	0.274	<.001	57	view →
LUAD	DFS	Tertile	All	1.000	0.694	.006	11	view →
CCRCC	DFS	Tertile	All	0.686	1.000	.024	6	view →
HNSC	OS	Median	All	0.958	1.000	.020	4	view →
GBM	DFS	Quartile	All	0.503	0.283	.022	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CELF2–PDAC (OS)

Open the PDAC breakdown →